Literature DB >> 9403645

Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994.

M N Needle1, A Cnaan, J Dattilo, J Chatten, P C Phillips, S Shochat, L N Sutton, S N Vaughan, E H Zackai, H Zhao, P T Molloy.   

Abstract

OBJECTIVES: To estimate the rate of progression of plexiform neurofibroma after surgery and to identify prognostic factors that predict progression. STUDY
DESIGN: A retrospective review of the inpatient and outpatient records of 121 patients, who had 302 procedures on 168 tumors over a 20-year period at a single large pediatric referral center. Data on age, location, indication for surgery, and extent of resection was analyzed for prognostic significance.
RESULTS: The overall freedom from progression was 54%. Children < 10 years old had a shorter interval of tumor control than older children (p = 0.0004). Tumors of the head/neck/face fared worse than tumors of the extremities (p = 0.0003). Less extensive resection predicted shorter interval to progression (p < 0.0001). Indication for surgery was not of prognostic importance. In multivariable analysis older age and location in the extremities were predictors of a better outcome.
CONCLUSIONS: Tumor progression is a serious problem for children with plexiform neurofibroma. Younger children, children with tumors of the head/neck/face, and tumors that cannot be nearly completely removed are at particular risk. These data may be useful in helping clinicians decide which patients and which tumors are most likely to benefit from surgical intervention.

Entities:  

Mesh:

Year:  1997        PMID: 9403645     DOI: 10.1016/s0022-3476(97)70092-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  60 in total

1.  Surgical treatment of giant plexiform neurofibroma associated with pectus excavatum.

Authors:  Yi Ji; Bing Xu; Xuejun Wang; Wenying Liu; Siyuan Chen
Journal:  J Cardiothorac Surg       Date:  2011-09-28       Impact factor: 1.637

2.  Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Authors:  Michael J Ferguson; Steven D Rhodes; Li Jiang; Xiaohong Li; Jin Yuan; Xianlin Yang; Shaobo Zhang; Saeed T Vakili; Paul Territo; Gary Hutchins; Feng-Chun Yang; David A Ingram; D Wade Clapp; Shi Chen
Journal:  Pediatr Blood Cancer       Date:  2015-09-16       Impact factor: 3.167

3.  CT features of plexiform neurofibroma of the submandibular gland.

Authors:  M Aribandi; W E Wood; D M Elston; D L Weiss
Journal:  AJNR Am J Neuroradiol       Date:  2006-01       Impact factor: 3.825

4.  The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression.

Authors:  Michael J Fisher; Sandip Basu; Eva Dombi; Jian Q Yu; Brigitte C Widemann; Avrum N Pollock; Avital Cnaan; Hongming Zhuang; Peter C Phillips; Abass Alavi
Journal:  J Neurooncol       Date:  2007-12-11       Impact factor: 4.130

Review 5.  Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Authors:  Brigitte C Widemann
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

6.  Management of massive lower limb plexiform neurofibromatosis--when to intervene?

Authors:  K T Power; J Giannas; Z Babar; D A McGrouther
Journal:  Ann R Coll Surg Engl       Date:  2007-11       Impact factor: 1.891

7.  Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma.

Authors:  Jianqiang Wu; Jason T Crimmins; Kelly R Monk; Jon P Williams; Maureen E Fitzgerald; Susan Tedesco; Nancy Ratner
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

8.  Surgery for Peripheral Nerve Sheath Tumours of the Buttocks, Legs and Feet in 90 Patients With Neurofibromatosis Type 1.

Authors:  Reinhard E Friedrich; Caglayan T Tuzcu
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

9.  Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.

Authors:  Scott R Plotkin; Stephanie D Davis; Kent A Robertson; Srivandana Akshintala; Julian Allen; Michael J Fisher; Jaishri O Blakeley; Brigitte C Widemann; Rosalie E Ferner; Carole L Marcus
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

Review 10.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.